(Total Views: 733)
Posted On: 08/27/2021 5:37:06 PM
Post# of 149615
An overview of accelerated approval and some cancer drugs. Of note is this passage -
Quote:
A subsequent study, however, not only failed to confirm the PFS benefit but also showed ¨better survival¨ in the placebo group, prompting an ¨FDA safety alert" to use atezolizumab only with nab-paclitaxel, not paclitaxel, which was the chemotherapy partner in the later trial.
https://www.ajmc.com/view/fda-panel-votes-to-...gs-to-come
(2)
(0)Scroll down for more posts ▼
